p53 Antibody

9282:

ChIP Agarose , ChIP Magnetic , Immunoprecipitation , Western Blotting

p53 Antibody recognizes endogenous levels of total p53 protein. This antibody binding has been mapped to the amino terminus and DNA binding domain of human p53 protein. This antibody does not cross-react with with other p53-related proteins.

Polyclonal antibodies are produced by immunizing animals with a full-length human p53 fusion protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western blot analysis of extracts from HeLa cells transfected with non-targeted (-) or targeted (+) siRNA. p53 was detected using the p53 Antibody #9282, and p42 MAPK was detected using the p42 MAPK Antibody #9108. The p53 Antibody confirms silencing of p53 expression, and the p42 MAPK Antibody was used to control for loading and specificity of p53 siRNA.

Western Blotting

Western blot analysis of E. coli and Baculovirus-expressed p53 fusion proteins, using p53 Antibody.

Western Blotting

Western blot analysis of extracts from 293, COS, HeLa, A431 and NBT-II cells, untreated or UV-treated, using p53 Antibody.

Chromatin IP

Chromatin immunoprecipitations were performed with cross-linked chromatin from 4 x 10⁶ HCT116 cells treated with UV (100 J/m² followed by a 3 hour recovery) and either 5 μl of p53 Antibody or 2 μl of Normal Rabbit IgG #2729 using SimpleChIP^® Enzymatic Chromatin IP Kit (Magnetic Beads) #9003. The enriched DNA was quantified by real-time PCR using SimpleChIP^® Human CDKN1A Promoter Primers #6449, human MDM2 intron 2 primers, and SimpleChIP^® Human α Satellite Repeat Primers #4486. The amount of immunoprecipitated DNA in each sample is represented as signal relative to the total amount of input chromatin, which is equivalent to one.

The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).

1. Levine, A.J. (1997) Cell 88, 323-331.
2. Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
3. Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
4. Shieh, S.Y. et al. (1997) Cell 91, 325-334.
5. Chehab, N.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 13777-13782.
6. Honda, R. et al. (1997) FEBS Lett. 420, 25-27.
7. Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.
8. Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.
9. Hirao, A. et al. (2000) Science 287, 1824-1827.
10. Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.
11. Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.
12. Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.
13. Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.
14. Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.
15. Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.
16. Oda, K. et al. (2000) Cell 102, 849-862.
17. Ito, A. et al. (2001) EMBO J. 20, 1331-1340.
18. Sakaguchi, K. et al. (1998) Genes Dev. 12, 2831-2841.
19. Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.

• Russell, J. L. et al. (2002) ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol. Cell. Biol. 22, 1360-1368. Applications: Western Blotting
• Stansel, R. M. et al. (2002) p53 binds telomeric single strand overhangs and t-loop junctions in vitro. J. Biol. Chem. 277, 11625-11628. Applications: Immunological Electron Microscopy
• Vaghefi, H. and Neet, K.E. (2004) Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a post-translational modification mechanism of neurotrophin-induced tumor suppressor activation. Oncogene 23, 8078-8087. Applications: Western Blotting
• Daniely, Y. et al. (2002) Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation. Mol. Cell. Biol. 22, 6014-6022. Applications: IP Western Blotting

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know !

• 2524 p53 (1C12) Mouse mAb
• 9281 Phospho-p53 (Ser392) Antibody
• 9288 Phospho-p53 (Ser9) Antibody
• 9284 Phospho-p53 (Ser15) Antibody
• 9285 Phospho-p53 (Ser6) Antibody
• 9286 Phospho-p53 (Ser15) (16G8) Mouse mAb
• 9287 Phospho-p53 (Ser20) Antibody
• 9289 Phospho-p53 (Ser37) Antibody
• 9919 Phospho-p53 Antibody Sampler Kit
• 7074 Anti-rabbit IgG, HRP-linked Antibody
• 7720 Prestained Protein Marker, Broad Range (Premixed Format)
• 7727 Biotinylated Protein Ladder Detection Pack
• 7003 20X LumiGLO^® Reagent and 20X Peroxide

For Research Use Only. Not For Use In Diagnostic Procedures.